Drugs / APP-311
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04871074 | Nov 2018 → Oct 2023 | Alzheimer disease | University of Wisconsin, Madison | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APP-311 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5999955 ↗ |
| Known as | UCB-J | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04871074 ↗ |
| Modality | Diagnostic / imaging agent | “The PET radioligand \[C-11\]UCB-J is a marker of SV2A.” NCT04871074 ↗ |